Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00675116 |
This is a study to evaluate the safety, tolerability and pharmacokinetics of GW823296 following 28 days, once-daily repeat oral doses.
Condition | Intervention | Phase |
---|---|---|
Healthy Subjects |
Drug: GW823296 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Parallel Assignment, Safety Study |
Official Title: | A Single-Blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GW823296 After Once-Daily Repeated Oral Doses in Healthy Male and Female Subjects |
Estimated Enrollment: | 30 |
Study Start Date: | April 2008 |
Study Completion Date: | July 2008 |
Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
A female subject is eligible to participate if she is of:
Exclusion Criteria:
The subject should be referred to the treating physician for further evaluation, as appropriate.
An average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males), or an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). [NOTE: 1 unit = 240mL beer, 90mL wine, or 30mL hard liquor]
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | 110371 |
Study First Received: | April 24, 2008 |
Last Updated: | May 29, 2009 |
ClinicalTrials.gov Identifier: | NCT00675116 History of Changes |
Health Authority: | Australia: Department of Health and Ageing Therapeutic Goods Administration |
safety, healthy volunteers, GW823296, pharmacokinetics |
Healthy |